Stryker Co. (NYSE:SYK) Shares Acquired by West Oak Capital LLC

West Oak Capital LLC raised its position in shares of Stryker Co. (NYSE:SYK) by 26.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 380 shares of the medical technology company’s stock after purchasing an additional 80 shares during the quarter. West Oak Capital LLC’s holdings in Stryker were worth $137,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Tilia Fiduciary Partners Inc. grew its position in Stryker by 3.6% in the fourth quarter. Tilia Fiduciary Partners Inc. now owns 7,075 shares of the medical technology company’s stock worth $2,548,000 after buying an additional 243 shares during the last quarter. Sugarloaf Wealth Management LLC grew its holdings in shares of Stryker by 11.2% in the 4th quarter. Sugarloaf Wealth Management LLC now owns 496 shares of the medical technology company’s stock worth $179,000 after acquiring an additional 50 shares during the last quarter. ST Germain D J Co. Inc. raised its position in shares of Stryker by 14.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 2,362 shares of the medical technology company’s stock worth $850,000 after purchasing an additional 300 shares during the period. Rempart Asset Management Inc. lifted its holdings in shares of Stryker by 5.0% during the fourth quarter. Rempart Asset Management Inc. now owns 49,496 shares of the medical technology company’s stock valued at $17,821,000 after purchasing an additional 2,351 shares during the last quarter. Finally, Bath Savings Trust Co boosted its position in shares of Stryker by 0.7% in the 4th quarter. Bath Savings Trust Co now owns 113,412 shares of the medical technology company’s stock valued at $40,834,000 after purchasing an additional 823 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SYK has been the subject of a number of analyst reports. Barclays upped their price objective on shares of Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a research note on Thursday, October 31st. Robert W. Baird raised their price objective on shares of Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. StockNews.com upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research report on Thursday. Needham & Company LLC restated a “buy” rating and issued a $442.00 target price on shares of Stryker in a report on Tuesday. Finally, Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $370.00 to $445.00 in a research report on Monday, December 2nd. Four research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and an average price target of $405.80.

Insider Buying and Selling

In other news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 5.50% of the company’s stock.

Stryker Stock Performance

Shares of NYSE:SYK traded up $1.94 during midday trading on Friday, hitting $366.04. The company’s stock had a trading volume of 1,313,772 shares, compared to its average volume of 1,285,595. Stryker Co. has a fifty-two week low of $306.10 and a fifty-two week high of $398.20. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The stock has a market capitalization of $139.54 billion, a price-to-earnings ratio of 39.23, a PEG ratio of 2.82 and a beta of 0.95. The stock’s 50 day simple moving average is $375.42 and its 200 day simple moving average is $357.51.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The company had revenue of $5.49 billion for the quarter, compared to the consensus estimate of $5.37 billion. During the same period in the previous year, the business posted $2.46 EPS. The company’s revenue for the quarter was up 11.9% on a year-over-year basis. As a group, research analysts anticipate that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a $0.84 dividend. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.92%. This is a boost from Stryker’s previous quarterly dividend of $0.80. Stryker’s payout ratio is presently 36.01%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.